NO20064130L - Antineoplastiske kombinasjoner av CCI-779 og rituximab - Google Patents
Antineoplastiske kombinasjoner av CCI-779 og rituximabInfo
- Publication number
- NO20064130L NO20064130L NO20064130A NO20064130A NO20064130L NO 20064130 L NO20064130 L NO 20064130L NO 20064130 A NO20064130 A NO 20064130A NO 20064130 A NO20064130 A NO 20064130A NO 20064130 L NO20064130 L NO 20064130L
- Authority
- NO
- Norway
- Prior art keywords
- cci
- rituximab
- antineoplastic combinations
- antineoplastic
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Det beskrives anvendelse av en kombinasjon av CCI-779 og rituximab ved behandling av non-Hodgkin- lymfom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55212204P | 2004-03-11 | 2004-03-11 | |
PCT/US2005/007724 WO2005087265A1 (en) | 2004-03-11 | 2005-03-09 | Antineoplastic combinations of cci-779 and rituximab |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064130L true NO20064130L (no) | 2006-10-10 |
Family
ID=34964832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064130A NO20064130L (no) | 2004-03-11 | 2006-09-13 | Antineoplastiske kombinasjoner av CCI-779 og rituximab |
Country Status (21)
Country | Link |
---|---|
US (1) | US20050272758A1 (no) |
EP (1) | EP1722817A1 (no) |
JP (1) | JP2007528399A (no) |
KR (1) | KR20070027510A (no) |
CN (1) | CN1929863A (no) |
AR (1) | AR047988A1 (no) |
AU (1) | AU2005221675A1 (no) |
BR (1) | BRPI0508451A (no) |
CA (1) | CA2557005A1 (no) |
CR (1) | CR8571A (no) |
EC (1) | ECSP066835A (no) |
GT (1) | GT200500040A (no) |
IL (1) | IL177565A0 (no) |
NO (1) | NO20064130L (no) |
PA (1) | PA8625801A1 (no) |
PE (1) | PE20060002A1 (no) |
RU (1) | RU2389508C2 (no) |
SG (1) | SG150559A1 (no) |
SV (1) | SV2005002048A (no) |
TW (1) | TW200539869A (no) |
WO (1) | WO2005087265A1 (no) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
JP2006306743A (ja) * | 2005-04-26 | 2006-11-09 | Hamamatsu Photonics Kk | 体液処理方法 |
HUE026303T2 (hu) | 2005-07-25 | 2016-06-28 | Emergent Product Dev Seattle | B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
WO2008116163A1 (en) * | 2007-03-22 | 2008-09-25 | Oregon Health & Science University | Therapeutic drug combinations for treatment of b-cell malignancies |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
DK2132228T3 (da) | 2008-04-11 | 2011-10-10 | Emergent Product Dev Seattle | CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf |
PL2310011T3 (pl) | 2008-06-17 | 2013-12-31 | Wyeth Llc | Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine |
SG10202102855RA (en) | 2008-08-04 | 2021-05-28 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
CN102271708A (zh) * | 2008-11-13 | 2011-12-07 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗联合疗法及其用途 |
MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
US20130028895A1 (en) * | 2011-07-27 | 2013-01-31 | Gerald Wulf | Exosome inhibiting agents and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
DK1319008T3 (da) * | 2000-09-19 | 2009-02-09 | Wyeth Corp | Vandoplöselige rapamycinestere |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
UA78706C2 (en) * | 2001-06-01 | 2007-04-25 | Wyeth Corp | Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
EP1615640B1 (en) * | 2003-04-22 | 2007-01-24 | Wyeth | Antineoplastic combinations |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
-
2005
- 2005-03-02 AR ARP050100792A patent/AR047988A1/es unknown
- 2005-03-03 TW TW094106420A patent/TW200539869A/zh unknown
- 2005-03-04 GT GT200500040A patent/GT200500040A/es unknown
- 2005-03-08 PE PE2005000263A patent/PE20060002A1/es not_active Application Discontinuation
- 2005-03-09 CN CNA2005800077977A patent/CN1929863A/zh active Pending
- 2005-03-09 BR BRPI0508451-2A patent/BRPI0508451A/pt not_active IP Right Cessation
- 2005-03-09 US US11/075,509 patent/US20050272758A1/en not_active Abandoned
- 2005-03-09 WO PCT/US2005/007724 patent/WO2005087265A1/en active Application Filing
- 2005-03-09 EP EP05732252A patent/EP1722817A1/en not_active Withdrawn
- 2005-03-09 AU AU2005221675A patent/AU2005221675A1/en not_active Withdrawn
- 2005-03-09 KR KR1020067018038A patent/KR20070027510A/ko not_active Application Discontinuation
- 2005-03-09 CA CA002557005A patent/CA2557005A1/en not_active Abandoned
- 2005-03-09 JP JP2007502952A patent/JP2007528399A/ja not_active Withdrawn
- 2005-03-09 RU RU2006130623/14A patent/RU2389508C2/ru not_active IP Right Cessation
- 2005-03-09 SG SG200901440-8A patent/SG150559A1/en unknown
- 2005-03-10 SV SV2005002048A patent/SV2005002048A/es unknown
- 2005-03-10 PA PA20058625801A patent/PA8625801A1/es unknown
-
2006
- 2006-08-17 IL IL177565A patent/IL177565A0/en unknown
- 2006-08-24 CR CR8571A patent/CR8571A/es not_active Application Discontinuation
- 2006-09-11 EC EC2006006835A patent/ECSP066835A/es unknown
- 2006-09-13 NO NO20064130A patent/NO20064130L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2389508C2 (ru) | 2010-05-20 |
BRPI0508451A (pt) | 2007-07-24 |
CN1929863A (zh) | 2007-03-14 |
CA2557005A1 (en) | 2005-09-22 |
IL177565A0 (en) | 2006-12-10 |
SV2005002048A (es) | 2005-11-04 |
PA8625801A1 (es) | 2006-06-02 |
GT200500040A (es) | 2005-10-24 |
PE20060002A1 (es) | 2006-02-14 |
TW200539869A (en) | 2005-12-16 |
KR20070027510A (ko) | 2007-03-09 |
JP2007528399A (ja) | 2007-10-11 |
US20050272758A1 (en) | 2005-12-08 |
CR8571A (es) | 2007-02-05 |
AU2005221675A1 (en) | 2005-09-22 |
ECSP066835A (es) | 2006-11-24 |
EP1722817A1 (en) | 2006-11-22 |
WO2005087265A1 (en) | 2005-09-22 |
AR047988A1 (es) | 2006-03-15 |
RU2006130623A (ru) | 2008-04-20 |
SG150559A1 (en) | 2009-03-30 |
WO2005087265A8 (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064130L (no) | Antineoplastiske kombinasjoner av CCI-779 og rituximab | |
BR0211769A (pt) | Combinações antineoplásicas | |
EP1689348A4 (en) | OLIGOSACCHARIDE COMPOSITIONS AND ITS USE IN THE TREATMENT OF INFECTIONS | |
AU2003237367A1 (en) | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer | |
AU2001293553A1 (en) | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment | |
FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
IL178012A0 (en) | Diphenyl-indol-2-on compounds and their use in the treatment of cancer | |
DE60229922D1 (de) | Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend | |
EP1469877A4 (en) | B-cell lymphoma-specific antigen for use in the diagnosis and treatment of malignant B cell lesions | |
MXPA05010582A (es) | Combinaciones antineoplasicas. | |
IL173188A0 (en) | Use of alcohol-oxyalkyates in the form of adjuvants for benzamidoxime gungicidal derivatives, appropriate agents and kits | |
AU2001283285A1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
FR2834459B1 (fr) | Agent microbicide et composition de traitement cosmetique le contenant | |
IS6966A (is) | Cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
IS6967A (is) | Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
MXPA05001885A (es) | El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica. | |
AU2003274963A1 (en) | Mda-7 and free radicals in the treatment of cancer | |
EP1558238A4 (en) | BETA-HYDROXYPHENYL ALDYLAMINE AND ITS USE FOR THE TREATMENT OF GLAUCOMA | |
IL162941A0 (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
AU2003244455A1 (en) | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases | |
AU2003245858A1 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
SG112006A1 (en) | Radioactive arsenic-containing compounds and their uses in the treatment of tumors | |
AU2003270350A1 (en) | Isoxazoles and their use in the treatment of ischemic diseases | |
EP1684795A4 (en) | METHODS AND AGENTS FOR THE TREATMENT OF CANCER | |
GB0205395D0 (en) | Materials and methods relating to the treatment of lymphoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |